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Identity 
Other names: C20orf139, Npn3, SRX1, YKL086W, 
dJ850E9.2 




Human Srx is located on chromosome 20 in the region 
of p13. 
Description 
Human Srx gene is 6632 bp in length, composed of 2 
exons and located at chromosome 20p13. 
Transcription 
The size of Srx mRNA is 2580 bp. Srx transcript 
contains two exons. Exon 1 is 271 bp and exon 2 is 
2300 bp. The catalytic domain of Srx reducing enzyme 
activity is localized in exon 2. 
Protein 
Note 
Human Srx protein has a total of 137 amino acids and a 
14 kDa molecular weight. 
Description 
Srx is a member of antioxidant protein family 
containing a ParB-like nuclease domain. It forms 5 beta 
strands and 6 helix secondary structures. Srxn1 binds to 
peroxiredoxins (Prxs) and reduces overoxidized Prxs in 
the presence of cofactors including magnesium and 
ATP. 
Expression 
In adult, Srx protein was found in internal organs such 
as mouse liver and kidney. Expression pattern of Srx in 
embryonic development is not clear. Transcriptional 
regulation of Srx expression is mainly mediated 
through AP-1 and/or Nrf-2 activation (Jeong et al., 
2012). In yeast, it may also be negatively regulated at 
the translational level through Ras-PKA pathway 
(Molin et al., 2011). 
Localisation 
Srx is mainly localized in the cytosol. In the presence 
of severe oxidative stress, it may also translocate to 
mitochondria (Noh et al., 2009). 
Function 
Srx was first identified as a gene preferentially 
expressed in transformed JB6 cells (Sun et al., 1994).  
The primary biochemical function of Srx is to reduce 
the overoxidized cysteine residues of Prx I, Prx II, Prx 
III and Prx IV under severe oxidative stress (Biteau et 
al., 2003; Chang et al., 2004). The spectrum and 
specificity of its enzymatic function remains elusive. 
Srx may also cause the deglutathionylation of Prx II 
and others (Park et al., 2009; Findlay et al., 2006). The 
biological function of Srx may involve in the regulation 
of various cell signaling pathways to promote 
tumorigenesis and cancer progression. Abnormally 
high expression of Srx has been demonstrated in many 
malignant tumors including those of skin, lung, and 
colon (Wei et al., 2008). Srx may not be essential for 
development since Srx null mice are viable and normal 
(Planson et al., 2011). 
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Structure of Human Srx bound to an ATP molecule and Mg2+ in solution (NCBI). 
 
Homology 





Elevated expression of Srx has been associated with 
different types of human malignant tumors, such as 
skin squamous cell carcinoma, sweat gland carcinoma, 
basal cell carcinoma, melanoma, rectal carcinoma, lung 
adenocarcinoma and breast cancer (Wei et al., 2008; 
Hartikainen, et al., 2012). Increased Srx expression in 
lung cancer patients is positively associated with the 
deterioration of the clinic stages, and knockdown of 
Srx reduces cancer cell migration, invasion and their 
ability to form distal metastasis (Bowers et al., 2012; 
Wei et al., 2011). Srx genetic polymorphism of four 
SNPs (rs6116929, rs2008022, rs7269823, and 
rs9085283) is associated with breast cancer risk and 
patient survival (Hartikainen et al., 2011). 
Tissue injury 
Note 
Srx, together with Prxs, are required for the protection  
of tissues from oxidative stress induced damages by 




Srx is found to be expressed in alveolar macrophages in 
non-specific interstitial pneumonia and may contribute 
to the process of idiopathic pulmonary fibrosis (Mazur 
et al., 2010). 
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